The demonstration that oral immunization with lysates of Helicobacter or wi
th Helicobacter pylori urease can protect mice against H. felis infection o
pened the field of vaccine development against Helicobacter infections. Mor
e recently, the same antigen preparations were used successfully as a thera
peutic vaccine able to cure the infection, and additional protective antige
ns were identified. Evidence from animal studies suggests that protection i
s medicated by mucosal antibodies, in association with a T helper type 2 ce
ll cellular immune response. Vaccine adjuvants, delivery systems, and thera
peutic vaccination are likely to be the areas of major progress in the futu
re.